Abstract 4373384: Suboptimal Sleep Associates with Heightened Stress-Related Neurobiological and Leukopoietic Activity: Mediating Pathways to Cardiovascular Disease in Humans

Background: Suboptimal sleep (Sleep SO )—due to insufficient duration or sleep disorders—is prevalent and linked to cardiovascular disease (CVD) risk. Experimental data suggest a stress-driven neural-immune axis linking poor sleep to atherogenesis, but the mechanisms in humans remain uncertain. Hypotheses: 1) Sleep SO is associated with greater stress-related neural activity (SNA), increased leukopoietic activity, and higher incidence of major adverse cardiovascular events (MACE); 2) heightened SNA and leukopoiesis partly mediate the Sleep SO -MACE associations. Methods: We studied 46,827 Mass General Brigham Biobank (MGBB) participants (median age 58 years; 40% men). Sleep SO —defined as <7 h/night or an ICD–10–coded sleep disorder—was ascertained from baseline surveys and electronic records. SNA (AmygAc, the ratio of amygdalar to ventromedial prefrontal cortical activity) and leukopoietic activity (in bone marrow [BM] and spleen) were quantified by FDG PET/CT imaging. Incident MACE after consent was identified via ICD codes. Covariables—traditional cardiovascular risk factors (CVDRFs), Charlson Comorbidity Index (CCI), socioeconomic status (SES: income, employment, education, noise), lifestyle (obesity, exercise, alcohol), psychiatric history and a polygenic risk score (PRS) for coronary disease—were obtained from MGBB records. Multivariable regression and mediation analyses tested associations and pathways. Results: In age and sex adjusted models, Sleep SO associated with higher AmygAc (standardized β [95% CI]: 0.26 [0.10, 0.41], p=0.001; 1A ), BM (β [95% CI]: 0.22 [0.03, 0.40], p=0.023; 1B ), and splenic activities (β [95% CI]: 0.18 [0.08, 0.30], p<0.001; 1C ). Further, AmygAc associated with high BM (β: 0.15, p=0.002) and splenic activities (β: 0.15, p<0.001). Over a median 3.3 years follow-up, 2,033 subjects (1.4%) had MACE. Sleep SO associated with greater MACE risk (HR: 1.43; 95% CI: 1.29-1.59; p<0.001; 1D) after adjusting for CVDRFs. Prior associations persisted after further adjustment for lifestyle, psychiatric history, SES, CCI, and PRS. Mediation analyses showed that the Sleep SO -MACE link is serially mediated by SNA-BM pathways (log odds: 0.05, p<0.05; 1E ). Conclusions: Sleep SO is independently associated with elevated MACE risk through stress-mediated neural-immune pathways. These results highlight the need for routine sleep screening and suggest that sleep hygiene interventions may attenuate neural-immune activation and lower CVD risk.